Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study

• Published in: Translational lung cancer research Vol. 9; no. 5; pp. 1915 - 1923
• Main Authors: Ohara, Shuta, Suda, Kenichi, Sakai, Kazuko, Nishino, Masaya, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Fujino, Toshio, Koga, Takamasa, Hamada, Akira, Soh, Junichi, Nishio, Kazuto, Mitsudomi, Tetsuya
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 01.10.2020
• Subjects: Original; Circulating tumor DNA (ctDNA); prognostic factor; non-small cell lung cancer (NSCLC); recurrence-free survival (RFS); surgery
• ISSN: 2218-6751; 2226-4477
• DOI: 10.21037/tlcr-20-505

Recent studies of advanced lung cancer patients have shown that circulating tumor DNA (ctDNA) analysis is useful for molecular profiling, monitoring tumor burden, and predicting therapeutic efficacies and disease progression. However, the usefulness of ctDNA analysis in surgically resected lung cancers is unclear. This study included 20 lung cancer patients with clinical stage IIA-IIIA disease. Preoperative and postoperative (3-12 days) plasma samples were collected for ctDNA analysis. Cancer personalized profiling by deep sequencing, which can detect mutations in 197 cancer-related genes, was used for ctDNA detection. The cohort consisted of 18 men and 2 women with a median age of 69 (range, 37-88) years. Sixteen patients (80%) had a history of smoking. Histologically, there were four squamous cell carcinomas, 13 adenocarcinomas, two adenosquamous cell carcinomas, and one small cell carcinoma. At the time of data analysis, the 20 patients had been monitored for a median follow-up of 12 months. Eight patients (40%) were positive for preoperative ctDNA, and this was significantly correlated with tumor size (≥5 . <5 cm, P=0.018). Four patients (20%) were positive for postoperative ctDNA, and this was significantly correlated with histological grade (3 . 1 or 2, P=0.032). Postoperative positivity for ctDNA also predicted shorter recurrence-free survival (RFS) (P=0.015), while pre- and post-operative carcinoembryonic antigen levels (P=0.150 and P=0.533, respectively) and preoperative positivity for ctDNA (P=0.132) were not correlated with RFS. Detecting ctDNA postoperatively was a poor prognostic factor in surgically resected lung cancer patients that may suggest there is minimal residual disease (MRD).